Fig. 1From: Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trialStudy design. *Sequence of testing via inhaler 1, 2 and 3 for each patient will depend on randomizationBack to article page